Replimune Group Inc (REPL)

$5.01 +0.02 (0.40%)
Market Cap 411.60M
Revenue (ttm) 0.00
Net Income (ttm) -247.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.11
Volume 1,626,397
Avg Vol 10,565,773
Day's Range N/A - N/A
Shares Out 77.81M
Stochastic %K 14%
Beta 0.67
Analysts Sell
Price Target $5.57

Company Profile

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express a...

Industry: Biotechnology
Sector: Healthcare
Phone: (781) 222-9600
Address:
500 Unicorn Park Drive, Suite 303, Woburn, United States
ignoreo
ignoreo Aug. 12 at 4:28 PM
$REPL a must-watch https://www.youtube.com/watch?v=3myF9432BM8
0 · Reply
dogbone98
dogbone98 Aug. 12 at 4:00 PM
$REPL For Friday's options expiration, $5.00 kills the maximum number of calls and puts. Not that I'm saying stocks get manipulated like that, but, that's number.
0 · Reply
itsmejeremy
itsmejeremy Aug. 12 at 3:41 PM
$REPL
0 · Reply
ignoreo
ignoreo Aug. 12 at 1:51 PM
$REPL the question is WHEN they are granted AA and if they'll have to dilute to make it there. It all depends on how many people the FDA is willing to murder to save face from one of the dumbest CRLs in its history
0 · Reply
rahmanoof
rahmanoof Aug. 12 at 1:41 PM
$REPL up with low volume 😍
1 · Reply
LordsofKarma7
LordsofKarma7 Aug. 12 at 12:50 PM
$REPL
0 · Reply
ShorttradingElement
ShorttradingElement Aug. 12 at 12:29 PM
$REPL no one is covering at this level at this time of day when we know the dump is coming at the open. So who are the dimwits buying 2k shares just under resistance and thinking it’s a good place to enter or add…
1 · Reply
US_Bull
US_Bull Aug. 12 at 12:24 PM
$REPL Lols why sub 3$ is coming.
2 · Reply
bullbearcrab
bullbearcrab Aug. 12 at 9:27 AM
$REPL Easiest 2x of my life once they walk back the obviously wrong decision
1 · Reply
outlawinvestor1
outlawinvestor1 Aug. 12 at 5:59 AM
$REPL https://youtu.be/3myF9432BM8?si=AvUsCWVIaKb1AEP7
1 · Reply
Latest News on REPL
Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd

Aug 11, 2025, 8:04 AM EDT - 1 day ago

Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

Aug 9, 2025, 12:47 PM EDT - 3 days ago

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm

Replimune Group: The Prospects For FDA Approval After Rejection

Aug 7, 2025, 10:08 AM EDT - 5 days ago

Replimune Group: The Prospects For FDA Approval After Rejection

Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

Aug 7, 2025, 8:00 AM EDT - 5 days ago

Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

Why Is Replimune Stock Trading Lower On Monday?

Aug 4, 2025, 12:43 PM EDT - 8 days ago

Why Is Replimune Stock Trading Lower On Monday?

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

Aug 1, 2025, 10:51 AM EDT - 11 days ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune

REPL INVESTORS: Replimune Group, Inc. (NASDAQ:REPL) Investors may have been Affected by Fraud – Contact BFA Law by September 22 about Potentially Recovering Losses

Jul 30, 2025, 8:36 AM EDT - 13 days ago

REPL INVESTORS: Replimune Group, Inc. (NASDAQ:REPL) Investors may have been Affected by Fraud – Contact BFA Law by September 22 about Potentially Recovering Losses

REPL LAWSUIT: Replimune Group, Inc. Sued for Fraud after FDA Response Letter – Contact BFA Law by September 22 Court Deadline (NASDAQ:REPL)

Jul 28, 2025, 8:36 AM EDT - 15 days ago

REPL LAWSUIT: Replimune Group, Inc. Sued for Fraud after FDA Response Letter – Contact BFA Law by September 22 Court Deadline (NASDAQ:REPL)

Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm

Jul 25, 2025, 5:04 PM EDT - 17 days ago

Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is Facing a Securities Fraud Investigation – Investors with Losses are Notified to Contact BFA Law

Jul 24, 2025, 8:07 AM EDT - 19 days ago

REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is Facing a Securities Fraud Investigation – Investors with Losses are Notified to Contact BFA Law

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm

Jul 22, 2025, 2:56 PM EDT - 20 days ago

REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm

BREAKING: Replimune Group, Inc. Shares Drop 70%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Jul 22, 2025, 11:03 AM EDT - 21 days ago

BREAKING: Replimune Group, Inc. Shares Drop 70%; Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 11, 2025, 4:01 PM EDT - 4 weeks ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 1, 2025, 10:00 AM EDT - 2 months ago

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 2 months ago

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript

May 22, 2025, 11:19 AM EDT - 2 months ago

Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript

Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

May 22, 2025, 7:00 AM EDT - 2 months ago

Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day

May 16, 2025, 8:00 AM EDT - 3 months ago

Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 9, 2025, 4:01 PM EDT - 3 months ago

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

May 8, 2025, 5:00 AM EDT - 3 months ago

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

COYA

Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma

Apr 28, 2025, 3:26 PM EDT - 3 months ago

Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma

Replimune: A Misunderstood Contender In Oncolytics

Feb 12, 2025, 4:21 PM EST - 6 months ago

Replimune: A Misunderstood Contender In Oncolytics

Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

Feb 12, 2025, 8:00 AM EST - 6 months ago

Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 23, 2024, 8:00 AM EST - 8 months ago

Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch

Nov 29, 2024, 4:12 AM EST - 9 months ago

Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch

Replimune Announces Pricing of Upsized Public Offering

Nov 25, 2024, 11:55 PM EST - 9 months ago

Replimune Announces Pricing of Upsized Public Offering

Replimune Announces Proposed Public Offering

Nov 25, 2024, 7:09 AM EST - 9 months ago

Replimune Announces Proposed Public Offering

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Nov 21, 2024, 4:05 PM EST - 9 months ago

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

Nov 9, 2024, 1:00 PM EST - 9 months ago

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 30, 2024, 9:15 AM EDT - 10 months ago

Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024

Sep 15, 2024, 9:45 AM EDT - 11 months ago

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024

Replimune: Strong Data In A Highly Differentiated Space

Sep 3, 2024, 1:01 PM EDT - 1 year ago

Replimune: Strong Data In A Highly Differentiated Space

Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Replimune to Present at Two Upcoming Investor Conferences

Jul 30, 2024, 4:01 PM EDT - 1 year ago

Replimune to Present at Two Upcoming Investor Conferences

Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 7, 2024, 8:00 AM EDT - 1 year ago

Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma

Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 3, 2024, 8:00 AM EDT - 1 year ago

Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23, 2024, 5:00 PM EDT - 1 year ago

Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

ignoreo
ignoreo Aug. 12 at 4:28 PM
$REPL a must-watch https://www.youtube.com/watch?v=3myF9432BM8
0 · Reply
dogbone98
dogbone98 Aug. 12 at 4:00 PM
$REPL For Friday's options expiration, $5.00 kills the maximum number of calls and puts. Not that I'm saying stocks get manipulated like that, but, that's number.
0 · Reply
itsmejeremy
itsmejeremy Aug. 12 at 3:41 PM
$REPL
0 · Reply
ignoreo
ignoreo Aug. 12 at 1:51 PM
$REPL the question is WHEN they are granted AA and if they'll have to dilute to make it there. It all depends on how many people the FDA is willing to murder to save face from one of the dumbest CRLs in its history
0 · Reply
rahmanoof
rahmanoof Aug. 12 at 1:41 PM
$REPL up with low volume 😍
1 · Reply
LordsofKarma7
LordsofKarma7 Aug. 12 at 12:50 PM
$REPL
0 · Reply
ShorttradingElement
ShorttradingElement Aug. 12 at 12:29 PM
$REPL no one is covering at this level at this time of day when we know the dump is coming at the open. So who are the dimwits buying 2k shares just under resistance and thinking it’s a good place to enter or add…
1 · Reply
US_Bull
US_Bull Aug. 12 at 12:24 PM
$REPL Lols why sub 3$ is coming.
2 · Reply
bullbearcrab
bullbearcrab Aug. 12 at 9:27 AM
$REPL Easiest 2x of my life once they walk back the obviously wrong decision
1 · Reply
outlawinvestor1
outlawinvestor1 Aug. 12 at 5:59 AM
$REPL https://youtu.be/3myF9432BM8?si=AvUsCWVIaKb1AEP7
1 · Reply
itsmejeremy
itsmejeremy Aug. 12 at 3:12 AM
$REPL 🤡
0 · Reply
looking4sign
looking4sign Aug. 12 at 12:42 AM
$REPL https://www.linkedin.com/posts/kevin-harrington-013b4b3b_fda-cancer-oncodaily-activity-7356616811913580546-uSyp?utm_source=social_share_send&utm_medium=android_app&rcm=ACoAAAsx6xABL6cnO7i69yIk66ktoi2-DCKpwL8&utm_campaign=messages
0 · Reply
looking4sign
looking4sign Aug. 12 at 12:41 AM
$REPL good article about replimune https://www.linkedin.com/posts/kevin-harrington-013b4b3b_open-letter-to-the-fda-activity-7358000762498555904-5Ret?utm_source=social_share_send&utm_medium=android_app&rcm=ACoAAAsx6xABL6cnO7i69yIk66ktoi2-DCKpwL8&utm_campaign=messages
0 · Reply
rahmanoof
rahmanoof Aug. 11 at 10:53 PM
$REPL interesting
0 · Reply
ShorttradingElement
ShorttradingElement Aug. 11 at 8:14 PM
$REPL so much potential here. 🤣🧸📉
0 · Reply
Harvard_MBA
Harvard_MBA Aug. 11 at 8:13 PM
$REPL Another nice cornholing for longs. $2 is on its way, soon.
0 · Reply
WuPeifu
WuPeifu Aug. 11 at 6:50 PM
$REPL As I have said repeatedly - the stock has solid fundamentals and a decent backing, both institutionally and financially. This stock is a long term play, swing up or down in the short term, maybe it'll go lower than 5 if you want to buy, or it'll rocket - the price swings are wild and make little sense to me, but long term, I'm in.
1 · Reply
ignoreo
ignoreo Aug. 11 at 4:13 PM
interesting day $SRPT flat because sarepta bitch slapped vinay into the abyss, perception is he will be a good boy $CAPR down a shit ton because they have a dogshit drug with a snowball's chance in hell at approval under vinay $REPL down by only a little because vinay is regarded but the consensus is that the FDA made a mistake here
5 · Reply
LordsofKarma7
LordsofKarma7 Aug. 11 at 4:05 PM
$REPL massive potential still here
0 · Reply
rahmanoof
rahmanoof Aug. 11 at 3:59 PM
$REPL large calls volume for November 10 strike
0 · Reply
rogertrades
rogertrades Aug. 11 at 3:55 PM
$CAPR $SRPT $REPL Repl -6% down Sarepta flat (was 3% green earlier which I didn't follow) Capricor -13% down (expected but overreaction imo) Will Linda put a floor on the earnings call today. Tell us more about Hope - 3 please.
0 · Reply
chris_crack
chris_crack Aug. 11 at 2:35 PM
$REPL dead money
0 · Reply